Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.61 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980867 | 0.93 | METAP2 (0.52) | METAP2BRD4RAB9AHSD17B10MEN1 | |
| SCHEMBL3979170 | 0.90 | METAP2 (0.51) | METAP2BRD4RAB9AHSD17B10AGTR1 | |
| SCHEMBL3978709 | 0.89 | BRD4 (0.47) | METAP2BRD4RAB9AHSD17B10PKM | |
| SCHEMBL3986022 | 0.86 | METAP2 (0.50) | METAP2BRD4RAB9AHSD17B10MEN1 | |
| SCHEMBL3985573 | 0.86 | METAP2 (0.44) | METAP2BRD4RAB9A | |
| SCHEMBL3985586 | 0.86 | METAP2 (0.44) | METAP2BRD4RAB9A | |
| SCHEMBL3987768 | 0.84 | METAP2 (0.43) | METAP2BRD4RAB9AHSD17B10 | |
| SCHEMBL3987775 | 0.84 | METAP2 (0.43) | METAP2BRD4RAB9AHSD17B10 | |
| SCHEMBL3977662 | 0.83 | METAP2 (0.58) | METAP2BRD4RAB9A | |
| SCHEMBL3982282 | 0.83 | METAP2 (0.51) | METAP2BRD4RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491718-B2 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES (US) | 2009-02-17 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885BRD4 1361/4885RAB9A 3370/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | METAP2 1/4885BRD4 1361/4885RAB9A 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.